第六章:成人结核病预防治疗

IF 1.5 Q3 RESPIRATORY SYSTEM

Canadian Journal of Respiratory, Critical Care, and Sleep Medicine Pub Date : 2022-03-24 DOI:10.1080/24745332.2022.2039498

G. Alvarez, C. Pease, D. Menzies

{"title":"第六章:成人结核病预防治疗","authors":"G. Alvarez, C. Pease, D. Menzies","doi":"10.1080/24745332.2022.2039498","DOIUrl":null,"url":null,"abstract":"• Either once-weekly rifapentine and isoniazid for 3 months (3HP), or daily rifampin for 4 months (4R) is recommended. • When rifamycin based regimens cannot be used because they are not tolerated, not feasible or are contraindicated, the 9-month daily isoniazid regimen (9H) is the preferred option. • When the 9H regimen cannot be used, the six-month daily isoniazid regimen (6H) is recommended. • Evaluate for interactions between patients’ baseline medications and the prospective TPT regimen through an up-to-date drug decision support tool prior to treatment initiation.","PeriodicalId":9471,"journal":{"name":"Canadian Journal of Respiratory, Critical Care, and Sleep Medicine","volume":"53 1","pages":"77 - 86"},"PeriodicalIF":1.5000,"publicationDate":"2022-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"5","resultStr":"{\"title\":\"Chapter 6: Tuberculosis preventive treatment in adults\",\"authors\":\"G. Alvarez, C. Pease, D. Menzies\",\"doi\":\"10.1080/24745332.2022.2039498\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"• Either once-weekly rifapentine and isoniazid for 3 months (3HP), or daily rifampin for 4 months (4R) is recommended. • When rifamycin based regimens cannot be used because they are not tolerated, not feasible or are contraindicated, the 9-month daily isoniazid regimen (9H) is the preferred option. • When the 9H regimen cannot be used, the six-month daily isoniazid regimen (6H) is recommended. • Evaluate for interactions between patients’ baseline medications and the prospective TPT regimen through an up-to-date drug decision support tool prior to treatment initiation.\",\"PeriodicalId\":9471,\"journal\":{\"name\":\"Canadian Journal of Respiratory, Critical Care, and Sleep Medicine\",\"volume\":\"53 1\",\"pages\":\"77 - 86\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2022-03-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"5\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Canadian Journal of Respiratory, Critical Care, and Sleep Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/24745332.2022.2039498\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"RESPIRATORY SYSTEM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Canadian Journal of Respiratory, Critical Care, and Sleep Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/24745332.2022.2039498","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}

引用次数: 5

摘要

•推荐每周使用一次利福喷丁和异烟肼，持续3个月(3HP)，或每天使用利福平，持续4个月(4R)。•当利福霉素为基础的方案不能使用，因为他们不能耐受，不可行或禁忌，9个月每日异烟肼方案(9H)是首选。•当不能使用9H方案时，建议使用6个月每日异烟肼方案(6H)。•在治疗开始前，通过最新的药物决策支持工具评估患者基线药物与预期TPT方案之间的相互作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Chapter 6: Tuberculosis preventive treatment in adults

• Either once-weekly rifapentine and isoniazid for 3 months (3HP), or daily rifampin for 4 months (4R) is recommended. • When rifamycin based regimens cannot be used because they are not tolerated, not feasible or are contraindicated, the 9-month daily isoniazid regimen (9H) is the preferred option. • When the 9H regimen cannot be used, the six-month daily isoniazid regimen (6H) is recommended. • Evaluate for interactions between patients’ baseline medications and the prospective TPT regimen through an up-to-date drug decision support tool prior to treatment initiation.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Canadian Journal of Respiratory, Critical Care, and Sleep Medicine RESPIRATORY SYSTEM-

CiteScore

1.90

自引率

12.50%

发文量